Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a collaboration to further advance its psychedelic-assisted therapies. The company will be working with the University of Health Sciences Antigua, or UHSA, to pioneer clinical research and development of psychedelics within Antigua and Barbuda.
Under the collaboration, the duo intends to develop a psychedelic treatment centre within Antigua and Barbuda, which is expected to utilize Revive’s formulations and delivery forms of psychedelics. The centre as a result is expected to treat mental health and substance abuse disorders.
Also outlined under the arrangement, is research that is to take place on UHSA’s campus related to psychedelics will exclusive use Revive’s IP with the aim of the research being the foundation for novel psychedelic therapies for research and commercial use within the country. Clinical studies will be conducted as a result to support approvals in the Caribbean and to accelerate US FDA clinical development plans.
Finally, the duo will work on the establishment of a Master’s in Psychedelic Medicine for Doctor of Medicine students, and for those looking to expand their knowledge in the world of psychedelics.
“We are excited to partner with UHSA as the relationship complements and accelerates our research and commercial goals with psychedelics and advances our patented drug delivery technology to deliver psychedelics in an oral thin film patch and topical forms in human clinical studies to support regulatory approvals globally.”
Derrick Welsh, COO of Psilocin Pharma, a division of Revive
Revive Therapeutics last traded at $0.46 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
